Gonadotropin releasing hormone analogues for endometriosis

Drug and therapeutics bulletin · 1993 · vol. 31(6) , pp. 21–22 · doi:10.1136/dtb.31.6.21 · PMID:8348882 · W4231297543
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

GnRH analogues are marketed for endometriosis treatment by suppressing the estrogen secretion essential to this disorder.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Gonadotropin releasing hormone (GnRH) analogues are now marketed in the UK for the treatment of patients with endometriosis. Endometriosis is an oestrogen-dependent disorder, and conventional medical treatments have relied on mechanisms that oppose the effects of oestrogen, e.g. an androgen (danazol) or a progestagen (norethisterone). GnRH analogues work by suppressing oestrogen secretion.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-14T06:11:53.302379+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:39.448046+00:00
unpaywall
last seen: 2026-08-13T06:47:16.638238+00:00
License: CC0 · commercial use OK